Literature DB >> 19558472

Effect of cyclosporin A on functional recovery in the spinal cord following contusion injury.

Siobhan S McMahon1, Silke Albermann, Gemma E Rooney, Cathal Moran, Jacqueline Hynes, Yolanda Garcia, Peter Dockery, Timothy O'Brien, Anthony J Windebank, Frank P Barry.   

Abstract

Considerable evidence has shown that the immunosuppressant drug cyclosporin A (CsA) may have neuroprotective properties which can be exploited in the treatment of spinal cord injury. The aim of this study was to investigate the cellular environment within the spinal cord following injury and determine whether CsA has an effect on altering cellular interactions to promote a growth-permissive environment. CsA was administered to a group of rats 4 days after they endured a moderate contusion injury. Functional recovery was assessed using the Basso Beattie Bresnahan (BBB) locomotor rating scale at 3, 5 and 7 weeks post-injury. The rats were sacrificed 3 and 7 weeks post-injury and the spinal cords were sectioned, stained using histological and immunohistochemical methods and analysed. Using stereology, the lesion size and cellular environment in the CsA-treated and control groups was examined. Little difference in lesion volume was observed between the two groups. An improvement in functional recovery was observed within CsA-treated animals at 3 weeks. Although we did not see significant reduction in tissue damage, there were some notable differences in the proportion of individual cells contributing to the lesion. CsA administration may be used as a technique to control the cell population of the lesion, making it more permissive to neuronal regeneration once the ideal environment for regeneration and the effects of CsA administration at different time points post-injury have been identified.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19558472      PMCID: PMC2750760          DOI: 10.1111/j.1469-7580.2009.01107.x

Source DB:  PubMed          Journal:  J Anat        ISSN: 0021-8782            Impact factor:   2.610


  47 in total

Review 1.  Calcineurin signaling and muscle remodeling.

Authors:  E N Olson; R S Williams
Journal:  Cell       Date:  2000-06-23       Impact factor: 41.582

2.  Proliferation of NG2-positive cells and altered oligodendrocyte numbers in the contused rat spinal cord.

Authors:  D M McTigue; P Wei; B T Stokes
Journal:  J Neurosci       Date:  2001-05-15       Impact factor: 6.167

3.  Regulation of calcineurin by growth cone calcium waves controls neurite extension.

Authors:  N J Lautermilch; N C Spitzer
Journal:  J Neurosci       Date:  2000-01-01       Impact factor: 6.167

4.  Cyclosporin A treatment following spinal cord injury to the rat: behavioral effects and stereological assessment of tissue sparing.

Authors:  A G Rabchevsky; I Fugaccia; P G Sullivan; S W Scheff
Journal:  J Neurotrauma       Date:  2001-05       Impact factor: 5.269

5.  Cyclosporin A-sensitive signaling pathway involving calcineurin regulates survival of reactive astrocytes.

Authors:  B Pyrzynska; A Lis; G Mosieniak; B Kaminska
Journal:  Neurochem Int       Date:  2001-04       Impact factor: 3.921

Review 6.  Medical treatment and neuroprotection in traumatic brain injury.

Authors:  T Clausen; R Bullock
Journal:  Curr Pharm Des       Date:  2001-10       Impact factor: 3.116

7.  FK506 treatment inhibits caspase-3 activation and promotes oligodendroglial survival following traumatic spinal cord injury.

Authors:  Stephanie Nottingham; Pamela Knapp; Joe Springer
Journal:  Exp Neurol       Date:  2002-09       Impact factor: 5.330

8.  Involvement of the brain-derived neurotrophic factor/TrkB pathway in neuroprotecive effect of cyclosporin A in forebrain ischemia.

Authors:  K Miyata; N Omori; H Uchino; T Yamaguchi; A Isshiki; F Shibasaki
Journal:  Neuroscience       Date:  2001       Impact factor: 3.590

9.  Calcineurin controls nerve activity-dependent specification of slow skeletal muscle fibers but not muscle growth.

Authors:  A L Serrano; M Murgia; G Pallafacchina; E Calabria; P Coniglio; T Lømo; S Schiaffino
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-23       Impact factor: 11.205

10.  Analysis of FK506-mediated protection in an organotypic model of spinal cord damage: heat shock protein 70 levels are modulated in microglial cells.

Authors:  M-S Guzmán-Lenis; C Vallejo; X Navarro; C Casas
Journal:  Neuroscience       Date:  2008-06-05       Impact factor: 3.590

View more
  5 in total

1.  Tissue-engineered fibrin scaffolds containing neural progenitors enhance functional recovery in a subacute model of SCI.

Authors:  Philip J Johnson; Alexander Tatara; Dylan A McCreedy; Alicia Shiu; Shelly E Sakiyama-Elbert
Journal:  Soft Matter       Date:  2010-10-21       Impact factor: 3.679

2.  A pilot study of poly(N-isopropylacrylamide)-g-polyethylene glycol and poly(N-isopropylacrylamide)-g-methylcellulose branched copolymers as injectable scaffolds for local delivery of neurotrophins and cellular transplants into the injured spinal cord.

Authors:  Lauren Conova; Jennifer Vernengo; Ying Jin; B Timothy Himes; Birgit Neuhuber; Itzhak Fischer; Anthony Lowman; Jennifer Vernengo; Ying Jin; B Timothy Himes; Birgit Neuhuber; Itzhak Fischer; Anthony Lowman
Journal:  J Neurosurg Spine       Date:  2011-09-02

3.  Emerging molecular therapeutic targets for spinal cord injury.

Authors:  Shuo Wang; George M Smith; Michael E Selzer; Shuxin Li
Journal:  Expert Opin Ther Targets       Date:  2019-09-04       Impact factor: 6.902

Review 4.  Mitochondrial-Based Therapeutics for the Treatment of Spinal Cord Injury: Mitochondrial Biogenesis as a Potential Pharmacological Target.

Authors:  Natalie E Scholpa; Rick G Schnellmann
Journal:  J Pharmacol Exp Ther       Date:  2017-09-21       Impact factor: 4.030

5.  Cyclosporin A increases recovery after spinal cord injury but does not improve myelination by oligodendrocyte progenitor cell transplantation.

Authors:  He-Zuo Lü; Yan-Xia Wang; Jian-Sheng Zhou; Feng-Chao Wang; Jian-Guo Hu
Journal:  BMC Neurosci       Date:  2010-10-12       Impact factor: 3.288

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.